AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteCUDC-101 is a novel compound which inhibits multiple targets, which is designed to inhibit HDAC, EGFR and Her2.
More Information Supplier PageDebio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
More Information Supplier PageDebio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
More Information Supplier PageDebio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
More Information Supplier PageDebio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
More Information Supplier PageCUDC-907 is a single small molecule inhibitor that targets both PI3K and HDAC. CUDC-907 is more efficacious than either a single PI3K or HDAC inhibitor reference compound or a combination of the two single agents at maximally tolerated doses.
More Information Supplier PageCUDC-907 is a single small molecule inhibitor that targets both PI3K and HDAC. CUDC-907 is more efficacious than either a single PI3K or HDAC inhibitor reference compound or a combination of the two single agents at maximally tolerated doses.
More Information Supplier PageCUDC-907 is a single small molecule inhibitor that targets both PI3K and HDAC. CUDC-907 is more efficacious than either a single PI3K or HDAC inhibitor reference compound or a combination of the two single agents at maximally tolerated doses.
More Information Supplier PageCUDC-907 is a single small molecule inhibitor that targets both PI3K and HDAC. CUDC-907 is more efficacious than either a single PI3K or HDAC inhibitor reference compound or a combination of the two single agents at maximally tolerated doses.
More Information Supplier PageCUDC-907 is a single small molecule inhibitor that targets both PI3K and HDAC. CUDC-907 is more efficacious than either a single PI3K or HDAC inhibitor reference compound or a combination of the two single agents at maximally tolerated doses.
More Information Supplier PageCurcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells.
More Information Supplier PageCurcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells.
More Information Supplier PageCurcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells.
More Information Supplier PageCurcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells.
More Information Supplier PageCurcumol induces apoptosis via caspases-independent mitochondrial pathway in human lung adenocarcinoma ASTC-a-1 cells.
More Information Supplier PageCVT-6883, a selective A2B adenosine antagonist, represents a novel potential approach to treating cardiopulmonary diseases.
More Information Supplier PageCVT-6883, a selective A2B adenosine antagonist, represents a novel potential approach to treating cardiopulmonary diseases.
More Information Supplier PageCVT-6883, a selective A2B adenosine antagonist, represents a novel potential approach to treating cardiopulmonary diseases.
More Information Supplier PageCVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
More Information Supplier PageCVT-313 is a potent, selective, reversible, and ATP-competitive inhibitor of CDK2 (IC50 = 0.5 uM for Cdk2/A and Cdk2/E; 4.2 uM for Cdk1/B; 215 uM for Cdk4/D1).
More Information Supplier PageCW069 is an allosteric, and selective inhibitor of microtubule motor protein HSET with IC50 of 75 uM, significant selectivity over KSP.
More Information Supplier PageCW069 is an allosteric, and selective inhibitor of microtubule motor protein HSET with IC50 of 75 uM, significant selectivity over KSP.
More Information Supplier PageCW069 is an allosteric, and selective inhibitor of microtubule motor protein HSET with IC50 of 75 uM, significant selectivity over KSP.
More Information Supplier PageCW069 is an allosteric, and selective inhibitor of microtubule motor protein HSET with IC50 of 75 uM, significant selectivity over KSP.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageCX-4945 is a potent and selective orally bioavailable small molecule inhibitor of CK2 that inhibits human umbilical vein endothelial cell migration, tube formation, and blocks CK2-dependent hypoxia-induced factor 1 alpha (HIF-1??) transcription in cancer cells.
More Information Supplier PageCX-5461 is a first-in-class non-genotoxic small molecule targeted inhibitor of RNA polymerase I (Pol I) that activates the p53 pathway without causing DNA damage.
More Information Supplier PageCX-5461 is a first-in-class non-genotoxic small molecule targeted inhibitor of RNA polymerase I (Pol I) that activates the p53 pathway without causing DNA damage.
More Information Supplier PageCX-5461 is a first-in-class non-genotoxic small molecule targeted inhibitor of RNA polymerase I (Pol I) that activates the p53 pathway without causing DNA damage.
More Information Supplier PageCX-5461 is a first-in-class non-genotoxic small molecule targeted inhibitor of RNA polymerase I (Pol I) that activates the p53 pathway without causing DNA damage.
More Information Supplier PageCX-6258 is a potent, selective, and orally efficacious pan-Pim kinases inhibitor.
More Information Supplier PageCX-6258 is a potent, selective, and orally efficacious pan-Pim kinases inhibitor.
More Information Supplier PageCX-6258 is a potent, selective, and orally efficacious pan-Pim kinases inhibitor.
More Information Supplier PageCX-6258 HCl is a potent, orally efficacious pan-Pim kinase inhibitor with IC50 of 5 nM, 25 nM and 16 nM for Pim1, Pim2, and Pim3.
More Information Supplier PageCX-6258 HCl is a potent, orally efficacious pan-Pim kinase inhibitor with IC50 of 5 nM, 25 nM and 16 nM for Pim1, Pim2, and Pim3.
More Information Supplier PageCX-6258 HCl is a potent, orally efficacious pan-Pim kinase inhibitor with IC50 of 5 nM, 25 nM and 16 nM for Pim1, Pim2, and Pim3.
More Information Supplier PageCX-6258 HCl is a potent, orally efficacious pan-Pim kinase inhibitor with IC50 of 5 nM, 25 nM and 16 nM for Pim1, Pim2, and Pim3.
More Information Supplier PageCX-6258 hydrochloride hydrate is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity.
More Information Supplier PageCX-6258 hydrochloride hydrate is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity.
More Information Supplier PageCX-6258 hydrochloride hydrate is a potent, orally efficacious Pim 1/2/3 kinase(IC50=5 nM/25 nM/16 nM) inhibitor with excellent biochemical potency and kinase selectivity.
More Information Supplier PageCyanidin chloride is an anthocyanin polyphenolic antioxidant compound with demonstrated cell protectant effects.
More Information Supplier PageCyanidin chloride is an anthocyanin polyphenolic antioxidant compound with demonstrated cell protectant effects.
More Information Supplier PageCyanidin chloride is an anthocyanin polyphenolic antioxidant compound with demonstrated cell protectant effects.
More Information Supplier PageCyanidin-3-O-glucoside chloride is a natural anthocyanin found in the fruits of some plants.
More Information Supplier Page
